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Abstract
Cystic fibrosis (CF) is a chronic inflammatory disease that is affecting thousands of patients worldwide. Adjuvant
anti-inflammatory treatment is an important component of cystic fibrosis treatment, and has shown promise in
preserving lung function and prolonging life expectancy. Inhaled high molecular weight hyaluronan (HMW-HA) is
reported to improve tolerability of hypertonic saline and thus increase compliance, and has been approved in some
European countries for use as an adjunct to hypertonic saline treatment in cystic fibrosis. However, there are
theoretical concerns that HMW-HA breakdown products may be pro-inflammatory. In this clinical pilot study we
show that sputum cytokines in CF patients receiving HMW-HA are not increased, and therefore HMW-HA does not
appear to adversely affect inflammatory status in CF airways.
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Introduction
Dear Editor,
Cystic fibrosis is a chronic inflammatory disease that is
affecting thousands of patients worldwide. Although spe-
cific therapies like ivacaftor and lumacaftor/ivacaftor have
been approved, they have high costs and are not indicated
for all CF patients. Adjuvant anti-inflammatory treatment
is an important component of cystic fibrosis treatment,
and has shown promise in preserving lung function and
prolonging life expectancy [1].
Airway inflammation generates short-fragment HA
(sHA, MW 0.1-0.3 × 106 Da) via degradation of structural
high molecular hyaluronan (HMW-HA, MW> 106 Da) or
de novo expression, and further promotes inflammation
and airway hyperresponsiveness. HMW-HA antagonizes
sHA effects and has been studied therapeutically in animal
models of inflammatory airway disease, such as asthma [2]
and cystic fibrosis [3]. In addition, HMW-HA has been
recently approved in some European countries for use in
upper airway disease, and as an adjunct to hypertonic
saline treatment in cystic fibrosis. Inhaled HMW-HA is
reported to improve tolerability of hypertonic saline and
thus increase compliance [4, 5]. Because HMW-HA ame-
liorates airway inflammation and hyperresponsiveness, its
use in inflammatory lung disease has been advocated.
However, a major concern clouding the therapeutic use of
inhaled HMW-HA in inflammatory airway disease is that
it may itself be degraded to sHA and thus contribute to
inflammation. We, therefore, evaluated how chronic use
of inhaled HMW-HA affects inflammatory cytokines in
induced sputum of cystic fibrosis patients.
Methods
We compared patients who were converted from treatment
with hypertonic saline (HTS) to HTS with 0.1 % HMW-
HA (MW 0.3-0.5 × 106 Da, brand name Hyaneb®) because
they could not tolerate the HTS solution. We performed
two comparisons: 1) paired analysis in repeat sputa from
patients before, and 4–6 weeks after conversion from HTS
to HTS +HMW-HA; and 2) comparison of one group of
patients on HTS with another group on HTS +HMW-HA.
Patients were children and young adults with CF (11 male
and 2 female, age (average ± SD) 15.6 ± 4.7) (Table 1).
Results
Lung function did not change before and after conversion
in comparison 1 (FEV1/FVC pre 95.8 ± 11, FEV1/FVC post
97.1 ± 10.9), and was not different between groups in com-
parison 2. HMW-HA treatment did not increase induced
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sputum cytokine levels or HA levels in a significant manner
(in paired comparisons average ± SD, pre vs post: IL-1β:
369 ± 794 vs 511 ± 1093 pg/ml; IL-6: 1.003 ± 1.775 vs 1.528
± 1.968 ng/ml; IL-10: 1.140 ± 0.867 vs 1.225 ± 0.988 ng/ml;
GM-CSF: 4.759 ± 4.452 vs 4.065 ± 3.342 ng/ml; TNF-α:
5.115 ± 6.477 vs 6.178 ± 10.76 ng/ml; not shown for
between-groups comparison). There was large variability in
sputum HA levels (range 0.2–2081 ng/ml for pre-HMW-
HA, 0.2-1070 ng/ml for post-HMW-HA, mean and median
396 and 39.9 ng/ml for pre-HMW-HA, 163.7 and 85.3 ng/
ml for post-HMW-HA). Interestingly, in patients with low
initial HA levels in induced sputum, HTS +HMW-HA
treatment led to a statistically significant increase in sputum
HA levels. On the contrary, in patients with initially high
sputum HA levels, initiation of inhaled HMW-HA led to
no further increase, and perhaps a trend towards decreased
HA levels. Initiation of HMW-HA treatment was reflected
in an increase of HMW-HA in induced sputum (Fig. 1).
Discussion
There are several potential reasons explaining why
inhaled HMW-HA does not lead to increased inflamma-
tion in this population. First, even though there was
apparent degradation of inhaled HMW-HA, there were
still appreciable amounts of HMW-HA in induced spu-
tum, suggesting that the degradation does not affect the
entire inhaled dose. Thus, there may still be HMW-HA
available to antagonize sHA. Second, sHA generated
from the degradation of HMW-HA in the airway com-
partment may not reach interstitial immune cells in high
enough concentrations to cause their activation. Lastly,
sHA may not contribute significantly to inflammation in
the context of pre-existing severe airway inflammation,
although it is a proinflammatory agonist in the naïve lung.
Interestingly, 100–150 kDa HA fragments (i.e. sHA)
appear to be beneficial in the treatment of tobacco-
induced airway disease, [6, 7] whereas they induce airway
inflammation when given to naïve mice [8]. Thus, the the-
oretical concern about sHA aggravating airway disease
may not be relevant in the real-world setting of pre-
existing airway inflammation such as in cystic fibrosis or
other chronic inflammatory diseases.
Although there was no apparent harm from inhaled
HMW-HA in this population, there was also no apparent
benefit in lung function or inflammatory cytokine expres-
sion. This particular formulation of inhaled HMW-HA is
used to improve tolerability of HTS in CF [4, 9], not as an
anti-inflammatory agent; nevertheless, HMW-HA has
been previously shown to improve lung function in
asthma and COPD [10–12] and inflammation in an
animal model of CF [3]. Inhaled glycosaminoglycan for-
mulations may have a role in airway disease. Recently, an
exciting study reported significant improvements from in-
haled heparin in patients with severe COPD. Inhaled HA
has also been used successfully in COPD [6, 7, 13–15],
and two clinical trials (NCT00993707 and NCT02674880)
Table 1 Lung function and clinical characteristics of patients transitioned from HTS to HTS_HMW-HA. Lung function values are
expressed as % predicted
Patient FEV1/FEV P. aerug.
pre post gender age pre post inh Abx AZT BD inh CS dorn α
1 104 103 m 9 + - TOBI + + + +
2 101 104 m 19 - - colistin + + + -
3 95 85 f 13 - - TOBI + - - -
4 96 94 m 19 + + TOBI, colistin + + + -
5 113 113 m 18 - - - - + - -
6 102 104 m 8 - - - - - - -
7 87 102 m 16 + + TOBI - - - +
8 69 76 m 23 + + TOBI - - - +
9 104 104 m 23 + + TOBI, aztreonam + - - +
10 97 97 m 12 - - - - + + +
11 97 105 m 14 - - colistin + - - -
12 97 95 f 14 - - colistin, aztreonam + + + +
13 83 80 m 15 - - - - + + -
avg 95.8 97.1 15.6
SD 11.0 10.9 4.7
p 0.57
Abbreviations: avg average value, SD standard deviation, TOBI inhaled tobramycin, Abx antibiotics, AZT azithromycin, BD chronic bronchodilator treatment, CS
corticosteroids, p significance value in Wilcoxon matched-pairs, signed-rank test
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are currently underway evaluating efficacy of inhaled HA
in COPD. However, HA effects in asthma and COPD may
not parallel CF, where inflammation is more pronounced,
and may overwhelm HMW-HA effects; furthermore,
there are higher concentrations of sHA in CF [16] com-
pared to asthma [17] which may antagonize HMW-HA;
the thickness and tenacity of CF mucus may prevent HA
from penetrating sufficiently into the airway cells layer;
finally, lung function changes and inflammatory changes
in CF have different kinetics than the dynamic airway
obstruction in asthma, and thus the observation period in
this study may not have been sufficiently long to detect
changes. It is worth noting, that heparin demonstrated in
vitro mucolytic effects in CF sputum [18], but inhaled
heparin did not show significant improvement in lung
function in a pilot study of CF patients [19]. Furthermore,
some mechanisms of action of HA, such as inhibition of
elastases and matrix breakdown [13, 14, 20] are relevant
in COPD but not in CF. In aggregate, we believe that gly-
cosaminoglycans like heparin and HA are likely to be
effective in COPD and asthma, but that prolonged dosing,
or different formulations may be needed for CF patients.
An interesting finding of our study involves the di-
chotomous effect of inhaled HMW-HA on HA induced
sputum levels depending on initial concentration. In
patients with low pre-treatment HA concentrations (de-
fined as concentration < 100 ng/ml), initiation of treat-
ment with HMW-HA led to an increase in measured
levels. This may be reflecting the addition of inhaled
HMW-HA to the airway fluid, and would suggest that
inhaled HMW-HA does contribute to the HA pool in
the airways. Given that HA is extremely hydrophilic,
Fig. 1 Levels of inflammation-related cytokines and chemokines in induced sputa of CF patients before and at least one month after induction
of inhaled HMW-HA treatment (all patients were on hypertonic saline treatment throughout this period). Levels of HA in induced sputa
of CF patients without inhaled HMW-HA treatment and at least one month after induction of inhaled HMW-HA treatment. Left panel depicts comparison
of two separate groups of patients, on and off HMW-HA treatment, and right panel depicts HA levels in patients transitioned from HTS to HTS +HMW-HA
treatment. a Levels of HA in induced sputa of CF patients before and at least one month after induction of inhaled HMW-HA treatment, divided according
to initial HA levels prior to treatment initiation. b Agarose gel of HA sizes in induced sputa of CF patients before (lanes “a”) and at least
one month after induction (lanes “b”) of inhaled HMW-HA treatment. Patients 1–3 had low initial HA levels, and patients 4–6 had high
initial HA levels. In patients 1–3 there is apparent increase in HA, as well as shift of HA size towards larger molecular weights. In patients
4–6 there is evidence of decreased HA abundance but no apparent change in HA size
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such increase may help hydrate the airways and contrib-
ute to bacterial clearance and improved ciliary function.
More intriguing is the effect of inhaled HMW-HA when
patients had initially high endogenous HA levels
(>100 ng/ml): in this case there is an apparent decrease
in sputum HA, which is evident both via ELISA and gel
electrophoresis assays. It is possible that exogenous
HMW-HA exerts a negative feedback effect in sHA
generation, thus indirectly improving HA homeostasis
towards less sHA and more HMW-HA.
Conclusions
In summary, our results suggest that inhaled HMW-HA
therapy does not exacerbate inflammation in airway
disease, and may improve the HA homeostasis in inflamed
lungs. Thus, inhaled HMW-HA merits investigation as an
adjunct treatment for inflammatory airway disease.
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